IBRX
Closed
Immunitybio Inc
2.57
-0.07 (-2.65%)
Last Update: 01 Jul 2025 23:10:00
Yesterday: 2.64
Day's Range: 2.5 - 2.69
Send
sign up or login to leave a comment!
When Written:
1.81
Immunitybio Inc is a clinical-stage immunotherapy company based in Culver City, California, USA. The company is focused on developing next-generation immunotherapies that can target a wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. Immunitybio's approach is based on the use of a proprietary platform technology known as "heterologous prime-boost" that combines different types of vaccines and immunotherapies to stimulate the immune system in a more powerful and effective way. The company's lead product candidate, a COVID-19 vaccine called hAd5, has shown promising results in preclinical studies and is currently being evaluated in clinical trials. Immunitybio is also developing a range of other immunotherapies, including cancer vaccines, checkpoint inhibitors, and cytokine therapies. The company was founded in 2015 by Dr. Patrick Soon-Shiong, a physician and entrepreneur who has been involved in the development of several successful biotech companies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








